description Feng Zhang Overview
Feng Zhang is a Chinese-American bioengineer and neuroscientist who currently serves as a core institute member at the Broad Institute of MIT and Harvard. He is widely recognized for his central role in developing optogenetics and, most notably, for demonstrating that the CRISPR-Cas9 system could be adapted for genome editing in mammalian cells in 2013. His laboratory's research focuses on developing advanced molecular tools to manipulate and understand biological systems. These technological advancements are widely utilized by researchers across molecular biology, genetics, and therapeutic development.
help Feng Zhang FAQ
What institution is Feng Zhang affiliated with?
Feng Zhang is a core institute member at the Broad Institute of MIT and Harvard, and a professor at MIT in the Department of Biological Engineering. His lab focuses on developing molecular tools for neuroscience and genome editing.
What was Feng Zhang's contribution to CRISPR-Cas9 genome editing?
Zhang's lab published a landmark 2013 paper demonstrating that CRISPR-Cas9 could be adapted for genome editing in mammalian cells, which opened the door to potential therapeutic applications. This work paralleled Jennifer Doudna and Emmanuelle Charpentier's earlier foundational research on the CRISPR system.
Was Feng Zhang involved in the CRISPR patent dispute?
Yes, the Broad Institute, representing Zhang's work, was engaged in a years-long patent interference proceeding with the University of California, Berkeley, representing Doudna and Charpentier's work. The USPTO ultimately ruled that the Broad's patents covering CRISPR use in eukaryotic cells were distinct from UC Berkeley's broader claims.
What biotech companies has Feng Zhang co-founded?
Zhang co-founded Editas Medicine, one of the first companies pursuing CRISPR-based therapeutics, alongside other founders including Jennifer Doudna. He also co-founded Beam Therapeutics, which focuses on precision base-editing technology.
explore Explore More
Reviews & Comments
Write a Review
Be the first to review
Share your thoughts with the community and help others make better decisions.